Patents by Inventor Ellen Garber

Ellen Garber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240301043
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Application
    Filed: December 15, 2023
    Publication date: September 12, 2024
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Patent number: 12037398
    Abstract: The invention relates to anti-VLA-4 antibodies and binding fragments thereof. The invention further includes polynucleotides encoding said antibodies and binding fragments thereof and methods of manufacturing said antibodies and binding fragments thereof. The invention further includes methods of treating patients suffering from multiple sclerosis and/or epilepsy by administration of said antibodies and binding fragments thereof. The invention further includes methods of reducing the susceptibility to scrambling of a recombinant anti-alpha 4 antibody or a binding fragment thereof.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 16, 2024
    Assignee: Biogen MA Inc.
    Inventors: Janine Lisa Ferrant-Orgettas, Robert Blake Pepinsky, Ellen Duggan Cahir-McFarland, Nadia Giselle D'Lima, Joseph Walter Arndt, Karl John Mortley Hanf, Thomas Owen Cameron, Ellen Garber Stark
  • Patent number: 11879008
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: January 23, 2024
    Assignee: Q32 Bio Inc.
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Publication number: 20230135399
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD4OL) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Application
    Filed: September 7, 2022
    Publication date: May 4, 2023
    Inventors: LINDA C. BURKLY, JANINE L. FERRANT-ORGETTAS, ELLEN A. GARBER, YEN-MING HSU, LIHE SU, FREDERICK R. TAYLOR, RALPH ADAMS, DEREK THOMAS BROWN, ANDREW GEORGE POPPLEWELL, MARTYN KIM ROBINSON, ANTHONY SHOCK, KERRY LOUISE TYSON
  • Publication number: 20210395360
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: March 30, 2021
    Publication date: December 23, 2021
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber Stark, Steven D. Miklasz, Christilyn Graff
  • Publication number: 20210309728
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Application
    Filed: June 4, 2021
    Publication date: October 7, 2021
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Publication number: 20210238289
    Abstract: The invention relates to anti-VLA-4 antibodies and binding fragments thereof. The invention further includes polynucleotides encoding said antibodies and binding fragments thereof and methods of manufacturing said antibodies and binding fragments thereof. The invention further includes methods of treating patients suffering from multiple sclerosis and/or epilepsy by administration of said antibodies and binding fragments thereof. The invention further includes methods of reducing the susceptibility to scrambling of a recombinant anti-alpha 4 antibody or a binding fragment thereof.
    Type: Application
    Filed: May 31, 2019
    Publication date: August 5, 2021
    Applicant: BIOGEN MA INC.
    Inventors: Janine Lisa FERRANT-ORGETTAS, Robert Blake PEPINSKY, Ellen Duggan CAHIR-MCFARLAND, Nadia Giselle D'LIMA, Joseph Walter ARNDT, Karl John Mortley HANF, Thomas Owen CAMERON, Ellen Garber STARK
  • Patent number: 11053306
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: July 6, 2021
    Assignee: Q32 Bio Inc.
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Patent number: 11053305
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: July 6, 2021
    Assignee: Q32 Bio Inc.
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Publication number: 20210009669
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Application
    Filed: September 29, 2020
    Publication date: January 14, 2021
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Publication number: 20200317775
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: February 13, 2020
    Publication date: October 8, 2020
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber Stark, Steven D. Miklasz, Christilyn Graff
  • Publication number: 20200262895
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: September 24, 2019
    Publication date: August 20, 2020
    Applicants: Biogen MA Inc., Biogen International Neuroscience GmbH
    Inventors: Paul H. Weinreb, Feng Chen, Ellen A. Garber Stark, Jan Grimm, Fabio Montrasio
  • Publication number: 20200181249
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Application
    Filed: January 24, 2020
    Publication date: June 11, 2020
    Inventors: MICHAEL STEVEN CURTIS, MICHAEL STOREK, SHELIA MARIE VIOLETTE, SUSAN L. KALLED, KELLY C. FAHNOE, CHENG RAN HUANG, ELLEN GARBER STARK, FREDERICK ROBBINS TAYLOR, JUSTIN ANDREW CARAVELLA, VERNON MICHAEL HOLERS
  • Publication number: 20190233530
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 1, 2019
    Inventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson
  • Patent number: 10336826
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: July 2, 2019
    Assignee: Biogen MA Inc.
    Inventors: Michael Karpusas, Paul D. Lyne, Ellen A. Garber Stark, Jose William Saldanha
  • Publication number: 20190169274
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: June 27, 2018
    Publication date: June 6, 2019
    Applicants: Biogen MA Inc., Biogen International Neuroscience GmbH
    Inventors: Paul H. Weinreb, Feng Chen, Ellen A. Garber Stark, Jan Grimm, Fabio Montrasio
  • Publication number: 20190161546
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: June 26, 2018
    Publication date: May 30, 2019
    Applicant: Biogen MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber Stark, Steven D. Miklasz, Christilyn Graff
  • Publication number: 20180362652
    Abstract: Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
    Type: Application
    Filed: January 12, 2018
    Publication date: December 20, 2018
    Applicant: Biogen MA Inc.
    Inventors: Justin A. Caravella, Ellen A. Garber Stark, Dania Mounir Rabah, Frederick R. Taylor
  • Patent number: 9902775
    Abstract: Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: February 27, 2018
    Assignee: Biogen MA Inc.
    Inventors: Justin A. Caravella, Ellen A. Garber Stark, Dania Mounir Rabah, Frederick R. Taylor
  • Publication number: 20170369560
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: February 8, 2017
    Publication date: December 28, 2017
    Applicants: Biogen MA Inc., Biogen International Neuroscience GmbH
    Inventors: Paul H. Weinreb, Feng Chen, Ellen A. Garber Stark, Jan Grimm, Fabio Montrasio